New Relevant Evidence in Cholangiocarcinoma Biology and Characterization DOI Open Access

N. M. Porro,

Elena Spínola-Lasso, Mirella Pastore

и другие.

Cancers, Год журнала: 2024, Номер 16(24), С. 4239 - 4239

Опубликована: Дек. 19, 2024

Among solid tumors, cholangiocarcinoma (CCA) emerges as one of the most difficult to eradicate. The silent and asymptomatic nature this tumor, particularly in its early stages, well high heterogeneity at genomic, epigenetic, molecular levels delay diagnosis, significantly compromising efficacy current therapeutic options thus contributing a dismal prognosis. Extensive research has been conducted on pathobiology CCA, recent advances have made classification characterization new targets. Both targeted therapy immunotherapy emerged effective safe strategies for various types cancers, demonstrating potential benefits advanced CCA. Furthermore, deeper comprehension cellular components tumor microenvironment (TME) opened up possibilities innovative treatment methods. This review discusses evidence biology highlighting novel possible druggable

Язык: Английский

Neoadjuvant Pemigatinib as a Bridge to Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangement DOI
Matthew Byrne, Richard F. Dunne, Jennifer I. Melaragno

и другие.

American Journal of Transplantation, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Язык: Английский

Процитировано

1

Apoptosis, MAPK signaling pathway affected in tilapia liver following nano-microplastics and sulfamethoxazole acute co-exposure DOI
Yao Zheng, Jiajia Li, Jiancao Gao

и другие.

Comparative Biochemistry and Physiology Part D Genomics and Proteomics, Год журнала: 2024, Номер 53, С. 101370 - 101370

Опубликована: Ноя. 28, 2024

Язык: Английский

Процитировано

1

Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine DOI
Cha Len Lee, Anna Saborowski, Arndt Vogel

и другие.

Expert Opinion on Pharmacotherapy, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 19, 2024

Despite a rising incidence, biliary tract cancers (BTC) are still considered rare tumor entity. The disease's subtle clinical presentation and lack of effective early detection strategies often lead to diagnosis at an advanced or unresectable stage, where curative options limited.

Язык: Английский

Процитировано

0

New Relevant Evidence in Cholangiocarcinoma Biology and Characterization DOI Open Access

N. M. Porro,

Elena Spínola-Lasso, Mirella Pastore

и другие.

Cancers, Год журнала: 2024, Номер 16(24), С. 4239 - 4239

Опубликована: Дек. 19, 2024

Among solid tumors, cholangiocarcinoma (CCA) emerges as one of the most difficult to eradicate. The silent and asymptomatic nature this tumor, particularly in its early stages, well high heterogeneity at genomic, epigenetic, molecular levels delay diagnosis, significantly compromising efficacy current therapeutic options thus contributing a dismal prognosis. Extensive research has been conducted on pathobiology CCA, recent advances have made classification characterization new targets. Both targeted therapy immunotherapy emerged effective safe strategies for various types cancers, demonstrating potential benefits advanced CCA. Furthermore, deeper comprehension cellular components tumor microenvironment (TME) opened up possibilities innovative treatment methods. This review discusses evidence biology highlighting novel possible druggable

Язык: Английский

Процитировано

0